2 results
Approved WMOCompleted
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
Approved WMOCompleted
primary objective:To evaluate the effect of individualised FE 999049 treatment on ovarian response in a long GnRH agonist protocol versus a GnRH antagonist protocolSecondary objectives:* To evaluate the effect of individualised FE 999049 treatment…